Expert Interview
Discussing the potential of Boehringer's Survodutide in Biopsy-Confirmed F1/F2/F3 MASH with a focus on the Phase II MASH trial
Ticker(s): BOEHRINGER INGELHEIM, ZEALInstitution: UT Southwestern Medical Center
- Associate Professor of Medicine in the Department of Internal Medicine at UT Southwestern and a member of the Division of Digestive and Liver Diseases
- Division Director of Clinical Research for Fatty Liver Disease
- Clinical practice focuses on the management of patients with a nonalcoholic fatty liver disease and patients with disorders of both the heart and liver
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
